This section highlights FDA-related milestones and regulatory updates for drugs developed by Bright Minds Biosciences (DRUG).
Over the past two years, Bright Minds Biosciences has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as
BMB-101-105, BMB-101, and BMB‑201. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.
Select a button below to view the list of FDA events for that drug.
BMB-101-105 FDA Regulatory Events
BMB-101-105 is a drug developed by Bright Minds Biosciences for the following indication: for the treatment of seizures associated with DEEs.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- BMB-101-105
- Announced Date:
- November 2, 2026
- Indication:
- for the treatment of seizures associated with DEEs.
Announcement
Bright Minds Biosciences Inc. nnounces that the U.S. Food and Drug Administration ("FDA") has notified the Company via email that its investigational new drug application ("IND") for Developmental and Epileptic Encephalopathies ("DEEs") and related Protocol BMB-101-105 has been placed on a partial clinical hold following the FDA’s review.
Read Announcement
BMB-101 FDA Regulatory Events
BMB-101 is a drug developed by Bright Minds Biosciences for the following indication: In adult patients with classic Absence Epilepsy and Developmental Epileptic Encephalopathy (DEE).
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- BMB-101
- Announced Date:
- January 6, 2026
- Indication:
- In adult patients with classic Absence Epilepsy and Developmental Epileptic Encephalopathy (DEE).
Announcement
Bright Minds Biosciences Inc. announced positive and significant topline results from its Phase 2 BREAKTHROUGH clinical trial evaluating BMB-101, a selective 5-HT2C biased agonist, in adult patients with drug-resistant Absence Seizures and Developmental and Encephalopathic Epilepsies.
AI Summary
Bright Minds reported positive topline results from the Phase 2 BREAKTHROUGH trial of BMB-101, a selective 5-HT2C biased agonist, in adults with drug-resistant Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE). The open-label study enrolled 24 patients; the efficacy-evaluable groups included 11 Absence and 6 DEE patients. The Absence cohort showed a 73.1% median reduction in seizures ≥3 seconds (p = 0.012). The DEE cohort had a 63.3% median reduction in major motor seizures. The study met its primary endpoints in both cohorts.
BMB-101 was generally well tolerated, with most adverse events rated mild or moderate and no treatment-related serious adverse events. Common events included respiratory infections, fatigue, constipation, headache and drowsiness. The drug also increased REM sleep by about 90% without changing total sleep time. Bright Minds is preparing global registrational trials and plans to share additional data during the year.Read Announcement
BMB‑201 FDA Regulatory Events
BMB‑201 is a drug developed by Bright Minds Biosciences for the following indication: Validated Preclinical Vascular Headache Model.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- BMB‑201
- Announced Date:
- September 4, 2025
- Indication:
- Validated Preclinical Vascular Headache Model
Announcement
Bright Minds Biosciences Inc. announced compelling preclinical results for its investigational compound BMB‑201, in a validated isosorbide dinitrate (ISDN) rat model of vascular headache. BMB-201 produced statistically significant reductions in facial mechanical allodynia across both male and female cohorts at 1 and 2 hours post-dose, compared to vehicle, and demonstrated greater effect sizes than sumatriptan at multiple timepoints.
AI Summary
Bright Minds Biosciences reported strong preclinical data for BMB-201 in an isosorbide dinitrate (ISDN) rat model of vascular headache. When given to male and female rats, BMB-201 significantly reduced facial mechanical allodynia at both 1 and 2 hours after dosing compared to a control treatment. In head-to-head tests against sumatriptan, BMB-201 showed larger effect sizes at multiple timepoints, including higher periorbital pain thresholds in males (86% vs. 81% at 1 hour; 53–64% vs. 44% at 2 hours) and females (76–100% vs. 56% at 1 hour; 80% vs. 63% at 2 hours).
These results were statistically significant (p < 0.05) and consistent across sexes, supporting the compound’s potential as a 5-HT2A/2C receptor agonist for headache and migraine treatment. The data underpin plans to advance BMB-201 into clinical development for vascular pain disorders.
Read Announcement
Free DRUG Stock Alerts